Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 598-malignant-breast-disorders-with-cc
    Ask Trek AI about this page

    Malignant Breast Disorders with CC: Inpatient Reimbursement Overview

    DRG 598 encompasses inpatient stays for malignant breast disorders with a Complication or Comorbidity, covering cases where malignant breast disease is accompanied by an additional condition that increases clinical complexity. This grouping matters for inpatient reimbursement because the Complication or Comorbidity status changes the Diagnosis-Related Group assignment and thus affects Centers for Medicare & Medicaid Services payment weights and hospital case-mix considerations.

    Customize your policy alerts

    Sign up for drg 598 policy alerts

    Get alerted when payer policies referencing 598 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 598 Overview

    DRG 598 covers hospital admissions for malignant breast disorders when a Complication or Comorbidity is present; cases typically include patients with invasive breast cancer or other malignant breast neoplasms who have an additional comorbid condition that affects care complexity. This Diagnosis-Related Group groups clinical resource use around surgical, oncologic, and postoperative management of breast malignancy with added clinical complexity. It matters for Medicare payment because the presence of a Complication or Comorbidity adjusts relative payment weights and influences inpatient reimbursement under Centers for Medicare & Medicaid Services rules. Payers and hospitals use this grouping to classify case mix and allocate inpatient resource payments.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Neoadjuvant and perioperative systemic therapy trials assessing tumor response and surgical outcomes: These studies enroll patients with operable or locally advanced malignant breast tumors who require inpatient care for complications or comorbidities (the CC in this DRG), testing different chemotherapy, endocrine, or targeted therapy sequences given before surgery to downstage tumors and increase breast-conserving surgery rates. Research focuses on pathologic complete response, rates of conversion to less extensive surgery, and perioperative complication profiles, which matter to providers for operative planning and to payers because treatment sequencing can affect length of stay, readmissions, and downstream surgical resource use.
    • Comparative effectiveness studies of surgical approaches and inpatient management for complex cases: Trials compare outcomes of mastectomy versus breast-conserving surgery with oncoplastic techniques or immediate reconstruction in patients with malignant breast disease complicated by significant comorbid conditions (the CC population), or evaluate different perioperative care pathways (eg enhanced recovery protocols, inpatient wound care strategies). These studies target patients at higher perioperative risk to determine which approaches reduce complications, ICU utilization, and hospitalization duration, providing evidence to guide coding, reimbursement decisions, and resource allocation for providers and payers.
    • Post-discharge survivorship and complication-prevention trials focused on high-risk inpatients: These studies follow patients who required inpatient management for malignant breast disease with complicating conditions to test interventions such as structured multidisciplinary follow-up, early home nursing, or targeted infection-prevention bundles to reduce surgical-site infections, lymphedema progression, and 30–90 day readmissions. The patient population includes older adults and those with comorbid illness who are more likely to generate additional inpatient and outpatient costs; results inform discharge planning, case management, and payer investments in transitional-care programs to lower total cost of care and improve long-term outcomes.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.